Imaging CRO Qureight will use its end-to-end imaging technology and services in a clinical trial analysing diffuse cutaneous Systemic Sclerosis (dcSSc).
SSc is a complex disease characterised by fibrosis, vasculopathy and inflammation in the lungs, skin and other vital organs. It is associated with high morbidity and mortality.
“Our AI-powered imaging platform delivers analysis beyond traditional metrics, providing precise, compartment-specific insights into lung disease,” said Qureight CCO Jessica Payne.
Clinical-stage biotechnology company Mediar Therapeutics is running the phase two EncompaSSc trial. Qureight’s AI-powered 3D quantitative imaging analytics platform will help to evaluate changes in compartment-specific lung biomarkers in people with dcSSc treated with MTX-474.
MTX-474 is a monoclonal antibody therapeutic. The treatment is a human monoclonal antibody designed to inhibit EphrinB2, a key protein that drives fibrosis in SSc. In the study, participants will receive treatment with MTX-474 every four weeks. Treatment response will be assessed at a 12 week interim analysis and an end-of-treatment visit at week 24.
“We are dedicated to changing the landscape of treatment approaches for fibrotic diseases, including systemic sclerosis, to drive real impact on patient outcomes,” said Mediar CMO Jeff Bornstein.
Qureight will use its platform to analyse high-resolution computed tomography images taken of participants’ lungs at screening, and at 24 weeks after treatment with MTX-474. Using precise quantitative imaging analytics of compartment-specific lung biomarkers, Qureight will provide a comprehensive view of changes within the lungs.
The study will use multiple Qureight imaging models, including:
- Glass8 for assessment of inflammatory signal
- Fibr8 for quantification of fibrotic lung change
- Vascul8 for evaluation of pulmonary vascular alterations
- Air8 for airway analysis
- Lung8 for comprehensive lung structural assessment
“Together, these AI-driven biomarkers offer a powerful approach to understanding disease activity and progression in systemic sclerosis,” said Payne.
The platform generates immediate results from detailed analyses to support insights into disease stabilisation or progression following treatment.
